Aclarion (NASDAQ:ACON) versus iSpecimen (NASDAQ:ISPC) Head to Head Contrast

Aclarion (NASDAQ:ACON) and iSpecimen (NASDAQ:ISPC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.

Earnings and Valuation

This table compares Aclarion and iSpecimen”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$75,730.00	106.63	-$7.23 million	($17.01)	-0.19
iSpecimen	$1.93 million	2.24	-$10.49 million	($94.00)	-0.06

Aclarion has higher earnings, but lower revenue than iSpecimen. Aclarion is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Aclarion has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, iSpecimen has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Aclarion and iSpecimen, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1	0	0	0	1.00
iSpecimen	1	0	0	0	1.00

Insider & Institutional Ownership

7.5% of Aclarion shares are owned by institutional investors. Comparatively, 13.6% of iSpecimen shares are owned by institutional investors. 0.8% of Aclarion shares are owned by company insiders. Comparatively, 12.2% of iSpecimen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Aclarion and iSpecimen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aclarion	-9,517.11%	-52.31%	-49.79%
iSpecimen	-543.37%	-496.31%	-133.56%

Summary

iSpecimen beats Aclarion on 6 of the 11 factors compared between the two stocks.

About Aclarion

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

About iSpecimen

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.